Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis

Japanese Journal of Ophthalmology

Volumn 56, Issue 6, 2012, Pages 544-550

  Kim, Kyoung Min ^a   Shin, Yong Tae ^b   Kim, Hong Kyun ^b  

^a Nune Eye Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Autologous serum; Persistent epithelial defect; Platelet rich plasma

Indexed keywords

EPIDERMAL GROWTH FACTOR; EYE DROPS; FIBRONECTIN; RETINOL; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ADULT; AGED; ARTICLE; BLOOD AUTOTRANSFUSION; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CORNEA INJURY; DISEASE SEVERITY; EPITHELIZATION; FEMALE; HUMAN; KERATITIS; MALE; PERSISTENT CORNEA EPITHELIUM DEFECT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; THERAPY EFFECT; THROMBOCYTE COUNT; THROMBOCYTE RICH PLASMA; TREATMENT OUTCOME; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORNEAL DISEASES; CORNEAL ULCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; EPITHELIUM, CORNEAL; EYE INFECTIONS, BACTERIAL; FEMALE; FIBRONECTINS; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PLATELET COUNT; PLATELET-RICH PLASMA; RETROSPECTIVE STUDIES; SERUM; TRANSFORMING GROWTH FACTOR BETA; VITAMIN A; WOUND HEALING;

EID: 84872199819     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-012-0175-y     Document Type: Article

References (52)

1. Watanabe K, Nakagawa S, Nishida T. Stimulatory effects of fibronectin and EGF on migration of corneal epithelial cells. Invest Ophthalmol Vis Sci. 1987;28:205-11. (Pubitemid 17015741)
2. Tsubota K, Xu KP, Fujihara T, Katagiri S, Takeuchi T. Decreased reflex tearing is associated with lymphocytic infiltration in lacrimal glands. J Rheumatol. 1996;23:313-20. (Pubitemid 26079224)
3. Tsubota K. New approaches in dry eye management. Supplying missing components to the ocular surface epithelium. Current opinions in the Kyoto Cornea Club. Amsterdam: Kugler Publications; 1997.
4. Barton K, Nava A, Monroy DC, Pflugfelder SC. Cytokines and tear function in ocular surface disease. Adv Exp Med Biol. 1998;438:461-9. (Pubitemid 28303774)
5. Wilson SE, Linag Q, Kim WJ. Lacrimal gland HGF, KGF and EGF mRNA levels increase after corneal epithelial wounding. Invest Opthalmology Vis Sci. 1999;40:2185-90. (Pubitemid 29418371)
6. Panchoi S, Tullo A, Khaliq A, Foreman D, Boulton M. The effects of growth factors and conditioned media on the proliferation of human corneal epithelial cells and keratocytes. Graefes Arch Clin Exp Ophthalmol. 1998;236:1-8. (Pubitemid 28080563)
7. Fukuda M, Fullard RJ, Willcox MD, Baleriola-Lucas C, Bestawros F, Sweeney D, et al. Fibronectin in the tear film. Invest Ophthalmol Vis Sci. 1996;37:459-67. (Pubitemid 26057073)
8. Lopez Bernal D, Ubels JL. Artificial tear composition and promotion of recovery of the damaged corneal epithelium. Cornea. 1993;12:133-8.
9. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984; 27:459-61. (Pubitemid 14134788)
10. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106:1984-9.
11. Young AL, Cheng AC, Ng HK, Cheng LL, Leung GY, Lam DS. The use of autologous serum tears in persistent corneal epithelial defects. Eye. 2004;18:609-14. (Pubitemid 38961454)
12. Matsumoto Y, Dogru M, Goto E, Ohashi Y, Kojima T, Ishida R, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111:1115-20. (Pubitemid 38736990)
13. Nishida T, Nakamura M, Ofuji K, Reid TW, Mannis MJ, Murphy CJ. Synergistic effect of substance P with insulin-like growth factor-1 on epithelial migration of the cornea. J Cell Physiol. 1996;169:159-66. (Pubitemid 26342525)
14. van Setten GB, Viinikka L, Tervo T, Pesonen K, Tarkkanen A, Perheentupa J. Epidermal growth factor is a constant component of normal human tear fluid. Graefes Arch Clin Exp Ophthalmol. 1989;227:184-7. (Pubitemid 19066687)
15. Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder SC. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res. 1996;14:605-14. (Pubitemid 26276535)
16. Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler E, Cerra F. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet derived wound healing formula. Surg Gynecol Obstet. 1990;170:56-9.
17. Esnesto C. Growth factors and their potential clinic value. J Clin Endocrinol Metab. 1992;170:56-69.
18. Lynch SE, Colvin RB, Antoniades HN. Growth factors in wound healing: single and synergistic effects in partial thickness porcine skin wounds. J Clin Invest. 1989;84:640-6. (Pubitemid 19196999)
19. Alio JL, Abad M, Artola A, Rodriguez-Prats JL, Pastor S, Ruiz-Colecha J. Use of autologous platelet rich plasma in the treatment of dormant corneal ulcers. Ophthalmology. 2007;114:1286-93.
20. Alio JL, Pastor S, Ruiz-Colecha J, Rodriguez A, Artola A. Treatment of ocular surface syndrome after LASIK with autologous platelet rich plasma. J Refract Surg. 2007;23:617-9. (Pubitemid 46932386)
21. Katsui G. Assay methods of vitamin A. Assay methods of vitamin A in blood and tissues (in Japanese). Vitamins. 1982;56:97-101. (Pubitemid 12136408)
22. Scardovi C, De Felice GP, Gazzaniga A. Epidermal growth factor in the topical treatment of traumatic corneal ulcers. Ophthalmology. 1993;206:119-24. (Pubitemid 23145016)
23. Pastor JC, Calonge M. Epidermal growth factor and corneal wound healing: a multicenter study. Cornea. 1992;11:311-4.
24. Collins MK, Perkins GR, Rodriguez-Tarduchy G, Nieto MA, López-Rivas A. Growth factors as survival factors: regulation of apoptosis. Bioessays. 1994;16:133-8.
25. Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL, et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci. 1997;110:113-21. (Pubitemid 27075856)
26. Haber M, Cao Z, Panjwani N, Bedenice D, Li WW, Provost PJ. Effects of growth factors (EGF, PDGF-BB and TGF beta 1) on cultured equine epithelial cells and keratocytes: implications for wound healing. Vet Ophthalmol. 2003;6:211-7. (Pubitemid 37237427)
27. Vesaluoma M, Teppo AM, Gronhagen-Riska C, Tervo T. Release of TGF-beta 1 and VEGF in tears following photorefractive keratectomy. Curr Eye Res. 1997;16:19-25. (Pubitemid 27085148)
28. Spigelman AV, Deutsch TA, Sugar J. Application of homologous fibronectin to persistent human corneal epithelial defects. Cornea. 1987;6:128-30. (Pubitemid 17123212)
29. Nishida T, Nakagawa S, Awata T, Ohashi Y, Watanabe K, Manabe R. Fibronectin promotes epithelial migration of cultured rabbit cornea in situ. J Cell Biol. 1983;97:1653-7. (Pubitemid 14230230)
30. Nishida T, Nakagawa S, Awata T, Nishibayashi C, Manabe R. Rapid preparation of purified autologous fibronectin eyedrops from patient's plasma. Jpn J Ophthalmol. 1982;26:416-24. (Pubitemid 13180730)
31. Nishida T, Ohashi Y, Awata T, Manabe R. Fibronectin. A new therapy for corneal trophic ulcer. Arch Ophthalmol. 1983;101:1046-8. (Pubitemid 13067497)
32. Pfister RR, Renner ME. The corneal and conjunctival surface in vitamin A deficiency: a scanning electron microscopy study. Invest Ophthalmol Vis Sci. 1978;17:874-83. (Pubitemid 8389870)
33. Sommer A. Xerophthalmia and vitamin A status. Prog Retin Eye Res. 1998;17:9-31. (Pubitemid 28040751)
34. Ubels JL, Iorfino A, O'Brien WJ. Retinoic acid decreases the number of EGF receptors in corneal epithelium and Chang conjunctival cells. Exp Eye Res. 1991;52:763-5.
35. Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea. 2001;20:807-10. (Pubitemid 33029476)
36. del Castillo JM, de la Casa JM, Sardiña RC, Fernández RM, Feijoo JG, Gómez AC, et al. Treatment of recurrent corneal erosions using autologous serum. Cornea. 2002;21:781-3.
37. Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I, et al. Treatment of dry eye by autologous serum application in Sjögren's syndrome. Br J Ophthalmol. 1999;83:390-5. (Pubitemid 29161176)
38. Poon AC, Geerling G, Dart JK, Fraenkel G, Daniels J. Autologous serum eyedrops for dry eye and epithelial defect: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001;85:1188-97. (Pubitemid 32929543)
39. Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, McCarty DJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20:802-6. (Pubitemid 33029475)
40. Noble BA, Loh RSK, MacLennan S, Pesudovs K, Reynolds A, Bridges LR, et al. Comparison of autologous serum eyedrops with conventional therapy in a randomized controlled crossover trial for ocular surface disease. Br J Ophthalmol. 2004;88:647-52. (Pubitemid 38526648)
41. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91:4-15. (Pubitemid 38111215)
42. Stassen JM, Arnout J, Deckmyn H. The hemostatic system. Curr Med Chem. 2004;11:2245-60. (Pubitemid 39172347)
43. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res. 2002;22:913-22. (Pubitemid 35155690)
44. Boehlen F, Clemetson KJ. Platelet chemokines and their fusion practice? Transfus Med. 2001;11:403-17.
45. Englert SJ, Estep TH, Ellis-Stoll CC. Autologous platelet gel applications during cardiovascular surgery: effect on wound healing. J Extra Corpor Technol. 2005;37:148-52. (Pubitemid 40967324)
46. Sammartino G, Tia M, Marenzi G, di Lauro AE, D'Agostino E, Claudio PP. Use of autologous platelet-rich plasma in periodontal defect treatment after extraction of impacted mandibular third molars. J Oral Maxillofac Surg. 2006;63:766-70. (Pubitemid 40745289)
47. Choi BH, Im CJ, Huh JY, Suh JJ, Lee SH. Effect of platelet-rich plasma on bone regeneration in autologous bone graft. Int J Oral Maxillofac Surg. 2004;33:56-9.
48. Marx RE. Platelet rich plasma: what is platelet-rich plasma and what is not platelet-rich plasma? Implant Dent. 2001;10:225-8.
49. Man D, Plosker H, Winland-Brown JE. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast Reconstr Surg. 2001;107:229-37.
50. Bhanot S, Alex JC. Current applications of platelet gels in facial plastic surgery. Facial Plast Surg. 2002;18:27-33. (Pubitemid 34133954)
51. Hartwig D, Harloff S, Liu L, Schlenke P, Wedel T, Geerling G. Epitheliotrophic capacity of a growth factor preparation produced from platelet concentrates on corneal epithelial cells: a potential agent for the treatment of ocular surface defects? Transfusion. 2004;44:1724-31. (Pubitemid 39644057)
52. Gospodarowicz D, Bialecki H, Thakral TK. The angiogenic activity of the fibroblast and epidermal growth factor. Exp Eye Res. 1979;28:501-14. (Pubitemid 9174795)